NO20042635L - 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin - Google Patents

5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin

Info

Publication number: NO20042635L
Authority: NO; Norway
Prior art keywords: sulfanyl; medicine; triazole derivatives; triazole; derivatives
Prior art date: 2001-11-28

Application number

NO20042635A

Other languages

English (en)

Inventor

Marie-Odile Galcera Contour

Christophe Thurieau

Pierre Roubert

Alban Sidhu

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-28

Filing date

2004-06-23

Publication date

2004-06-23

2001-11-28 Priority claimed from FR0115342A external-priority patent/FR2832710B1/fr

2004-06-23 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2004-06-23 Publication of NO20042635L publication Critical patent/NO20042635L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20042635A 2001-11-28 2004-06-23 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin NO20042635L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0115342A FR2832710B1 (fr)	2001-11-28	2001-11-28	Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments
FR0207697		2002-06-21
PCT/FR2002/004055 WO2003045926A1 (fr)	2001-11-28	2002-11-27	Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicament

Publications (1)

Publication Number	Publication Date
NO20042635L true NO20042635L (no)	2004-06-23

Family

ID=26213278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042635A NO20042635L (no)	2001-11-28	2004-06-23	5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin

Country Status (22)

Country	Link
US (1)	US20050154039A1 (no)
EP (1)	EP1465880B1 (no)
JP (1)	JP2005513035A (no)
KR (1)	KR100961332B1 (no)
CN (1)	CN100462359C (no)
AR (1)	AR037465A1 (no)
AT (1)	ATE438630T1 (no)
AU (1)	AU2002361345B8 (no)
BR (1)	BR0214553A (no)
CA (1)	CA2468184A1 (no)
CZ (1)	CZ2004760A3 (no)
DE (1)	DE60233265D1 (no)
ES (1)	ES2330927T3 (no)
HU (1)	HUP0402489A3 (no)
MX (1)	MXPA04005099A (no)
MY (1)	MY133406A (no)
NO (1)	NO20042635L (no)
NZ (1)	NZ533397A (no)
PL (1)	PL370140A1 (no)
RU (1)	RU2367655C2 (no)
TW (1)	TWI283670B (no)
WO (1)	WO2003045926A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI252847B (en) *	2001-07-10	2006-04-11	Synta Pharmaceuticals Corp	Synthesis of taxol enhancers
TWI332943B (en) *	2001-07-10	2010-11-11	Synta Pharmaceuticals Corp	Taxol enhancer compounds
TWI297335B (en)	2001-07-10	2008-06-01	Synta Pharmaceuticals Corp	Taxol enhancer compounds
TWI330079B (en) *	2003-01-15	2010-09-11	Synta Pharmaceuticals Corp	Treatment for cancers
EP2305642A3 (en) *	2004-06-23	2011-12-14	Synta Pharmaceuticals Corp.	Bis(thio-hydrazide amide) salts for treatment of cancers
BRPI0518315B8 (pt)	2004-11-18	2021-05-25	Synta Pharmaceuticals Corp	compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
CA2604907A1 (en) *	2005-04-15	2006-10-26	Synta Pharmaceuticals Corp.	Combination cancer therapy with bis(thiohydrazide) amide compounds
CA2618628C (en) *	2005-08-18	2014-11-18	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
WO2007139955A2 (en) *	2006-05-25	2007-12-06	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
TW200800260A (en)	2006-05-25	2008-01-01	Synta Pharmaceuticals Corp	Method for treating proliferative disorders associated with protooncogene products
WO2007139960A2 (en) *	2006-05-25	2007-12-06	Synta Pharmaceuticals Corp.	Compounds that modulate hsp90 activity and methods for identifying same
BRPI0716435A2 (pt)	2006-08-21	2014-03-04	Synta Pharmaceuticals Corp	Compostos para o tratamento de doenças proliferativas
AU2007290490B2 (en) *	2006-08-31	2011-09-08	Synta Pharmaceuticals Corp.	Combination with bis(thiohydrazide amides) for treating cancer
US8258301B2 (en) *	2007-05-15	2012-09-04	Boehringer Ingelheim International Gmbh	Urotensin II receptor antagonists
KR100980328B1 (ko) *	2007-12-14	2010-09-06	한국생명공학연구원	단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
CN101981012A (zh)	2008-03-26	2011-02-23	第一三共株式会社	新的四氢异喹啉衍生物
CN101684103B (zh) *	2008-09-22	2011-04-06	天津药物研究院	1,2,4-三唑结构的化合物、其制备方法和用途
US8785488B2 (en)	2009-02-12	2014-07-22	Exelixis Patent Company Llc	Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity
WO2011133520A1 (en)	2010-04-19	2011-10-27	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2013067162A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en)	2011-11-02	2020-07-14	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013142346A1 (en) *	2012-03-23	2013-09-26	The Regents Of The University Of California	Premature-termination-codons readthrough compounds
CN103755652B (zh) *	2013-12-20	2015-08-05	陕西理工学院	一种磺酰胺类化合物及其应用
CN104370844A (zh) *	2014-10-29	2015-02-25	广西师范大学	3-硫酮-5-巯基甲基-1,2,4-三唑的合成方法
CN106831529A (zh) *	2016-12-11	2017-06-13	湖南华腾制药有限公司	一种三氟甲基吲哚衍生物的制备方法
BR112019016433A2 (pt)	2017-02-08	2020-04-07	Ono Pharmaceutical Co	composto que apresenta atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
US11912687B2 (en)	2017-05-12	2024-02-27	Board of Trustees of the Southern Illinois University	3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
WO2018209267A2 (en) *	2017-05-12	2018-11-15	Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville	3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
CN109666022B (zh) *	2017-10-17	2021-06-15	中国科学院上海药物研究所	三氮唑衍生物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0409332A3 (en) *	1989-07-19	1991-08-07	Merck & Co. Inc.	Substituted triazoles as angiotensin ii antagonists
US5177095A (en) *	1990-02-13	1993-01-05	Merck & Co., Inc.	Triazole angiotensin II antagonists incorporating a substituted benzyl element
GB2263635A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substitiuted triazoles as neurotensin antagonists
AU5533394A (en) *	1993-11-12	1995-05-29	Gyogyszerkutato Intezet Kft	Ulcer-inhibiting triazole derivatives, pharmaceutical compositions containing them and process for preparing same
DE4425144A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
US6080772A (en) *	1995-06-07	2000-06-27	Sugen, Inc.	Thiazole compounds and methods of modulating signal transduction
DE19600934A1 (de) *	1996-01-12	1997-07-17	Basf Ag	Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
WO1998056376A1 (en) *	1997-06-13	1998-12-17	Sugen, Inc.	Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
CN1319094A (zh) *	1998-06-12	2001-10-24	研究及应用科学协会股份有限公司	咪唑基衍生物
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
RU2002133666A (ru) *	2000-05-19	2007-05-10	Мерк Патент ГмбХ (DE)	Производные триазола

2002
- 2002-11-27 DE DE60233265T patent/DE60233265D1/de not_active Expired - Lifetime
- 2002-11-27 TW TW091134432A patent/TWI283670B/zh active
- 2002-11-27 US US10/496,820 patent/US20050154039A1/en not_active Abandoned
- 2002-11-27 CA CA002468184A patent/CA2468184A1/fr not_active Abandoned
- 2002-11-27 NZ NZ533397A patent/NZ533397A/en not_active IP Right Cessation
- 2002-11-27 EP EP02796876A patent/EP1465880B1/fr not_active Expired - Lifetime
- 2002-11-27 MX MXPA04005099A patent/MXPA04005099A/es active IP Right Grant
- 2002-11-27 WO PCT/FR2002/004055 patent/WO2003045926A1/fr not_active Ceased
- 2002-11-27 PL PL02370140A patent/PL370140A1/xx not_active Application Discontinuation
- 2002-11-27 KR KR1020047008002A patent/KR100961332B1/ko not_active Expired - Fee Related
- 2002-11-27 RU RU2004119406/04A patent/RU2367655C2/ru not_active IP Right Cessation
- 2002-11-27 JP JP2003547378A patent/JP2005513035A/ja active Pending
- 2002-11-27 AU AU2002361345A patent/AU2002361345B8/en not_active Ceased
- 2002-11-27 ES ES02796876T patent/ES2330927T3/es not_active Expired - Lifetime
- 2002-11-27 HU HU0402489A patent/HUP0402489A3/hu unknown
- 2002-11-27 MY MYPI20024450A patent/MY133406A/en unknown
- 2002-11-27 AT AT02796876T patent/ATE438630T1/de not_active IP Right Cessation
- 2002-11-27 CZ CZ2004760A patent/CZ2004760A3/cs unknown
- 2002-11-27 BR BR0214553-7A patent/BR0214553A/pt not_active IP Right Cessation
- 2002-11-27 CN CNB028276248A patent/CN100462359C/zh not_active Expired - Fee Related
- 2002-11-28 AR ARP020104601A patent/AR037465A1/es unknown
2004
- 2004-06-23 NO NO20042635A patent/NO20042635L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MY133406A (en)	2007-11-30
NZ533397A (en)	2005-12-23
AU2002361345B8 (en)	2008-06-26
KR100961332B1 (ko)	2010-06-04
HUP0402489A2 (hu)	2005-05-30
AU2002361345B2 (en)	2008-06-05
CA2468184A1 (fr)	2003-06-05
EP1465880B1 (fr)	2009-08-05
ES2330927T3 (es)	2009-12-17
ATE438630T1 (de)	2009-08-15
AR037465A1 (es)	2004-11-10
TWI283670B (en)	2007-07-11
TW200300760A (en)	2003-06-16
EP1465880A1 (fr)	2004-10-13
HK1070361A1 (zh)	2005-06-17
DE60233265D1 (de)	2009-09-17
KR20040062969A (ko)	2004-07-09
CZ2004760A3 (cs)	2005-01-12
AU2002361345A1 (en)	2003-06-10
JP2005513035A (ja)	2005-05-12
CN100462359C (zh)	2009-02-18
BR0214553A (pt)	2004-10-13
WO2003045926A1 (fr)	2003-06-05
RU2004119406A (ru)	2005-05-10
PL370140A1 (en)	2005-05-16
US20050154039A1 (en)	2005-07-14
MXPA04005099A (es)	2004-08-19
RU2367655C2 (ru)	2009-09-20
HUP0402489A3 (en)	2009-09-28
CN1617859A (zh)	2005-05-18

Publication	Publication Date	Title
NO20042635L (no)	2004-06-23	5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
NO20033566D0 (no)	2003-08-12	Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20035298D0 (no)	2003-11-28	CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DK1368349T3 (da)	2007-05-21	Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
NO20006029D0 (no)	2000-11-28	Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1455785T3 (da)	2009-06-08	Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20015156L (no)	2001-12-18	5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
NO20024175D0 (no)	2002-09-02	Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO20014603D0 (no)	2001-09-21	Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20021449L (no)	2002-05-07	Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20025357L (no)	2002-11-08	Antranylamider og deres anvendelse som legemidler
DK1095025T3 (da)	2003-04-07	Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
DK1445252T3 (da)	2006-06-19	Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
EE200300311A (et)	2003-10-15	Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
NO20005146D0 (no)	2000-10-13	Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20031838D0 (no)	2003-04-24	Benzokazinonderivater, deres fremstilling og anvendelse
NO20023146L (no)	2002-06-28	Substituerte fenyl-piperazinderivater, deres fremstilling og anvendelse
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1043307T3 (da)	2003-09-22	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1202996T3 (da)	2004-02-09	Titanforbindelser, fremstilling og anvendelse heraf
DK1532141T3 (da)	2010-11-22	2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
NO20033120L (no)	2003-09-11	2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav
NO20024107L (no)	2002-09-27	Tienopyridin derivater, deres fremstilling og anvendelse
NO20001782L (no)	2000-10-09	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse

Legal Events

Date	Code	Title	Description
2012-06-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application